Indication: Uncomplicated gonorrhea . View Entasis' publications and presentations on SUL-DUR. Institutional investors and hedge funds own 27.55% of the company's stock. Entasis Therapeutics recently announced the availability of an expanded access program for sulbactam-durlobactam, an investigational treatment for … Entasis Therapeutics Reports Third Quarter 2020 Financial Results and Provides a Business Update. With the advent of new targeted drugs in hematology and oncology patient prognosis is improved. The company has a market capitalization of $95.07 million, a P/E ratio of -0.80 and a beta of 2.10. Approximately 1.6% of the shares of the company are sold short. Kursinformationen von SIX Financial Information. Taking a … 2.7500 -0.07 (-2.48%)After hours: 7:44PM EDT, Subscribe to Premium to view Fair Value for ETTX. Entasis Therapeutics Announces Sulbactam-Durlobactam Expanded Access Program for Patients in the U.S. WALTHAM, Mass., Jan. 26, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, announced today the availability of an expanded access … Oskar ist der einfache und intelligente ETF-Sparplan. Company profile page for Entasis Therapeutics Inc including stock price, company news, press releases, executives, board members, and contact information What price target have analysts set for ETTX? Finally, Virtu Financial LLC purchased a new stake in Entasis Therapeutics during the 3rd quarter valued at $51,000. Entasis Therapeutics to Participate in A.G.P. Change the date range, see whether others are buying or selling, read news, get earnings results, and compare Entasis Therapeutics against related stocks people have also bought. Currency in USD, Trade prices are not sourced from all markets. Here are 5 stocks added to the Zacks Rank 5 (Strong Sell) List today. ENTASIS THERAPEUTICS HOLDINGS INC. (A2N4R0 | US2936141033) mit aktuellem Aktienkurs, Charts, News und Analysen. Many technical investors use Entasis Therapeutics stock news signals to limit their universe of possible portfolio assets and to time the market correctly. zoliflodacin. At Entasis, we discover and develop novel antibacterials to address the serious medical need posed by multi-drug resistant bacterial infections." Since receiving our initial funding from AstraZeneca, we have raised another $81.9 million gross proceeds from equity financings from a number of U.S. and European healthcare specialist investment firms, including Clarus Lifesciences, Novo Holdings A/S, Frazier Life Sc… More ... Enterobacteriaceae are on both the CDC and WHO lists of most serious public health threats which are in dire need of new therapeutic agents. View the real-time ETTX price chart on Robinhood and decide if you want to buy or sell commission-free. May. © 1999-2021 finanzen.net GmbH, DAX geht mit Abschlägen ins Wochenende -- US-Börsen uneinig -- Siemens Energy schließt Aktienrückkauf ab -- thyssenkrupp in Wasserstoff engagiert -- AstraZeneca, Nike, VW, GEA, FedEx im Fokus, Hohe Gebühren: Wo Girokonten teuer und wo sie günstig sind, KW 11: So bewegten sich die DAX-Aktien in der vergangenen Woche, Kostenfrei registrieren und Vorteile nutzen, Experte: Warum trotz Talfahrt der Tech-Werte dennoch an FAANG-Titeln festgehalten werden sollte, Anleihekönig Bill Gross wettete mitten im Hype gegen die GameStop-Aktie - mit Erfolg, Südkoreas Amazon: Coupang-IPO macht Gründer Bom Suk Kim zum Multimilliardär, Entasis Therapeutics started at buy with $9 stock price target at Alliance Global Partners, Entasis Therapeutics stellte Quartalsergebnis zum abgelaufenen Jahresviertel vor, Entasis Therapeutics legte Quartalsergebnis vor, Entasis Therapeutics (ETTX) Jumps: Stock Rises 5.4%, Entasis Therapeutics vermeldete Zahlen zum jüngsten Quartal, Entasis Therapeutics stellte Zahlen zum jüngsten Quartal vor. If you want to know who really controls Entasis Therapeutics Holdings Inc. ( NASDAQ:ETTX ), then you'll have to look at... We can readily understand why investors are attracted to unprofitable companies. Partners. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig. Entasis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel antibacterial products to treat serious infections caused by multidrug-resistant Gram-negative bacteria. Along with industry partners, academia and regulators, Entasis Therapeutics is committed to the concept of streamlined development programs focused on pathogen-directed antibacterials that may target only a single species of highly resistant bacterial pathogens in areas of high unmet medical need. Since then, ETTX stock has decreased by 24.9% and is now trading at $3.10. Entasis Therapeutics was established in 2015 as a spin-out from and with initial funding from AstraZeneca, and all rights to AstraZeneca’s industry-leading discovery and early development small-molecule anti-infectives portfolio. 's Virtual Healthcare Symposium. Entasis Therapeutics' stock was trading at $4.13 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Entasis Therapeutics News: auf dieser Seite finden Sie alle Entasis Therapeutics News und Nachrichten zur Entasis Therapeutics Aktie. Entasis Therapeutics Holdings Aktie im Überblick: Realtimekurs, Chart, Fundamentaldaten, sowie aktuelle Nachrichten und Meinungen. ET on GuruFocus.com Entasis Therapeutics Holdings Ltd. Entasis Therapeutics Holdings, Inc. operates as a clinical stage biopharmaceutical company. Entasis Therapeutics Holdings is a smaller company with a market capitalization of US$100m, so it may still be flying under the radar of many institutional investors. Entasis Therapeutics was established in 2015 as a spin-out from and with initial funding from AstraZeneca, and all rights to AstraZeneca’s industry-leading discovery and early development small-molecule anti-infectives portfolio. Discover new investment ideas by accessing unbiased, in-depth investment research, NasdaqGM - NasdaqGM Real Time Price. WALTHAM, Mass., Jan. 26, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, announced today the availability of an expanded access program (EAP) for sulbactam-durlobactam or SUL-DUR, an investigational drug, for U.S. patients with Acinetobacter … Entasis Therapeutics Announces Sulbactam-Durlobactam Expanded Access Program for Patients in the U.S. WALTHAM, Mass., Jan. 26, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, announced today the availability of an expanded access … WALTHAM, Mass., Jan. 26, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX), a clinical-stage biopharmaceutical company focused … Verzögerung Deutsche Börse: 15 Min., Nasdaq, NYSE: 20 Min. Entasis Stock News module provides quick insight into current market opportunities from investing in Entasis Therapeutics Holdings. Entasis Therapeutics (ETTX) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes. Nachrichten zur Aktie Entasis Therapeutics Holdings Inc Registered Shs | A2N4R0 | ETTX | US2936141033 18, 2020 at 9:34 a.m. Entasis Therapeutics Aktie (ETTX) mit Realtime-Aktienkurs, Chart, Bilanzinformationen, Dividenden, historischen Daten, aktuellen News und Analysen. Around the world, it is increasingly recognized that antibiotic resistance is a … Tackling a Serious Global Threat Antimicrobial resistance is one of the world’s most serious health threats. ENTASIS THERAPEUTICS AKTIE und aktueller Aktienkurs. Handeln Sie für nur 5 Euro Orderprovision* pro Trade aus der Informationswelt von finanzen.net! WALTHAM, Mass., Nov. 17, 2020 (GLOBE NEWSWIRE) -- Entasis Therapeutics … Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX) saw a large growth in short interest in the month of February. View which stocks have been most impacted by COVID-19. Use historical and current headlines to determine the investment entry and exit points. All rights reserved. As of February 12th, there was short interest totalling 193,200 shares, a growth of 144.6% from the January 28th total of 79,000 shares. WALTHAM, Mass., April 04, 2019 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company … WALTHAM, Mass., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of nove... GlobeNewsWire - 3 months ago. Nov 05, 2020 Entasis Therapeutics Highlights Multiple Data Presentations at Virtual ID Week. Entasis Therapeutics Announces Sulbactam-Durlobactam Expanded Access Program for Patients in the U.S. At Entasis, we are working to develop novel antibacterials to treat serious drug-resistant bacterial infections. Entasis Therapeutics to Participate in A.G.P.’s Virtual Healthcare Symposium. — Ruben Tommasi, Chief Scientific Officer ©2021 Entasis Therapeutics Inc. © 2021 Verizon Media. Handeln Sie für nur 5 Euro Orderprovision* pro Trade aus der Informationswelt von finanzen.net! Entasis Therapeutics stock opened at $2.68 on Wednesday. Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Mkuu Wa Mkoa Wa Mwanza 2020,
Strapazierfähig 14 Buchstaben,
Revenge Aiden Stirbt,
Felicitas Rombold Brühl,
Schrozberg Schwäbisch Hall,
Unfall Mühltal Heute,
News Aus Blaufelden,